Melphalan Sun

Melphalan, the active ingredient in Melphalan Sun, is an alkylating agent presented as an intravenous solution for intravenous use. It treats multiple myeloma, ovarian cancer, malignant melanoma, and other solid tumors.

GNH USA supplies Melphalan Sun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Melphalan is used in chemotherapy regimens targeting various malignant diseases.

- Multiple myeloma: improves disease control and prolongs survival. - Ovarian cancer: incorporated into combination protocols to reduce tumor burden. - Malignant melanoma: employed in high‑dose schedules for advanced disease. - Other solid tumors: applied where alkylating agents are indicated.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Bone marrow suppression: neutropenia, anemia, and thrombocytopenia may occur. - Fatigue: persistent tiredness reported by many patients. - Alopecia: reversible hair loss affecting scalp and body hair.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: due to profound immunosuppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis may develop.

Before initiating Melphalan therapy, clinicians should assess several safety parameters.

- Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess renal function: evaluate creatinine clearance prior to each cycle. - Evaluate pulmonary status: baseline lung function tests are recommended. - Avoid use in patients with known hypersensitivity to melphalan or related compounds. - Use effective contraception: teratogenic potential requires reliable birth control. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Live attenuated vaccines: risk of uncontrolled infection due to immunosuppression. - Concurrent alkylating agents: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk, monitor INR. - Non‑steroidal anti‑inflammatory drugs: may exacerbate renal toxicity. - ACE inhibitors or ARBs: potential for enhanced nephrotoxicity, check renal parameters.